Martina Pirro1, Yoann Rombouts2, Alexandre Stella2, Olivier Neyrolles2, Odile Burlet-Schiltz2, Sandra J van Vliet3, Arnoud H de Ru1, Yassene Mohammed1, Manfred Wuhrer1, Peter A van Veelen1, Paul J Hensbergen4. 1. Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands. 2. Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse, France. 3. Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands. 4. Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: P.J.Hensbergen@lumc.nl.
Abstract
BACKGROUND: The Ca2+-dependent C-type lectin receptor Macrophage Galactose-type Lectin (MGL) is highly expressed by tolerogenic dendritic cells (DC) and macrophages. MGL exhibits a high binding specificity for terminal alpha- and beta-linked GalNAc residues found in Tn, sTn and LacdiNAc antigens. These glycan epitopes are often overexpressed in colorectal cancer (CRC), and, as such, MGL can be used to discriminate tumor from the corresponding healthy tissues. Moreover, the high expression of MGL ligands is associated with poor disease-free survival in stage III of CRC tumors. Nonetheless, the glycoproteins expressed by tumor cells that are recognized by MGL have hitherto remained elusive. METHODS: Using a panel of three CRC cell lines (HCT116, HT29 and LS174T), recapitulating CRC diversity, we performed FACS staining and pull-down assays using a recombinant soluble form of MGL (and a mutant MGL as control) combined with mass spectrometry-based (glyco)proteomics. RESULTS: HCT116 and HT29, but not LS174T, are high MGL-binding CRC cell lines. On these cells, the major cell surface binding proteins are receptors (e.g. MET, PTK7, SORL1, PTPRF) and integrins (ITGB1, ITGA3). From these proteins, several N- and/or O-glycopeptides were identified, of which some carried either a LacdiNAc or Tn epitope. CONCLUSIONS: We have identified cell surface MGL-ligands on CRC cell lines. GENERAL SIGNIFICANCE: Advances in (glyco)proteomics have led to identification of candidate key mediators of immune-evasion and tumor growth in CRC.
BACKGROUND: The Ca2+-dependent C-type lectin receptor Macrophage Galactose-type Lectin (MGL) is highly expressed by tolerogenic dendritic cells (DC) and macrophages. MGL exhibits a high binding specificity for terminal alpha- and beta-linked GalNAc residues found in Tn, sTn and LacdiNAc antigens. These glycan epitopes are often overexpressed in colorectal cancer (CRC), and, as such, MGL can be used to discriminate tumor from the corresponding healthy tissues. Moreover, the high expression of MGL ligands is associated with poor disease-free survival in stage III of CRC tumors. Nonetheless, the glycoproteins expressed by tumor cells that are recognized by MGL have hitherto remained elusive. METHODS: Using a panel of three CRC cell lines (HCT116, HT29 and LS174T), recapitulating CRC diversity, we performed FACS staining and pull-down assays using a recombinant soluble form of MGL (and a mutant MGL as control) combined with mass spectrometry-based (glyco)proteomics. RESULTS:HCT116 and HT29, but not LS174T, are high MGL-binding CRC cell lines. On these cells, the major cell surface binding proteins are receptors (e.g. MET, PTK7, SORL1, PTPRF) and integrins (ITGB1, ITGA3). From these proteins, several N- and/or O-glycopeptides were identified, of which some carried either a LacdiNAc or Tn epitope. CONCLUSIONS: We have identified cell surface MGL-ligands on CRC cell lines. GENERAL SIGNIFICANCE: Advances in (glyco)proteomics have led to identification of candidate key mediators of immune-evasion and tumor growth in CRC.
Authors: Martina Pirro; Yassene Mohammed; Arnoud H de Ru; George M C Janssen; Rayman T N Tjokrodirijo; Katarina Madunić; Manfred Wuhrer; Peter A van Veelen; Paul J Hensbergen Journal: Int J Mol Sci Date: 2021-05-20 Impact factor: 5.923
Authors: Kubra F Naqvi; Matthew B Huante; Tais B Saito; Mark A Endsley; Benjamin B Gelman; Janice J Endsley Journal: J Immunol Date: 2021-06-28 Impact factor: 5.426
Authors: Pablo Valverde; J Daniel Martínez; F Javier Cañada; Ana Ardá; Jesús Jiménez-Barbero Journal: Chembiochem Date: 2020-07-02 Impact factor: 3.461
Authors: Martina Pirro; Yassene Mohammed; Sandra J van Vliet; Yoann Rombouts; Agnese Sciacca; Arnoud H de Ru; George M C Janssen; Rayman T N Tjokrodirijo; Manfred Wuhrer; Peter A van Veelen; Paul J Hensbergen Journal: Int J Mol Sci Date: 2020-08-01 Impact factor: 5.923
Authors: Donella M Beckwith; Forrest G FitzGerald; Maria C Rodriguez Benavente; Elizabeth R Mercer; Anna-Kristin Ludwig; Malwina Michalak; Herbert Kaltner; Jürgen Kopitz; Hans-Joachim Gabius; Maré Cudic Journal: Biochemistry Date: 2021-02-09 Impact factor: 3.162